You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
Roche, Eli Lilly, and others aim to elucidate differences in T2D patients in order to develop better diagnostic tools and new treatments.
The project team is driving the development of practice guidelines because sample handling and quality are often not up to the mark.